TrialIndian journal of ophthalmology2022

A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis

Ramandeep Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.